Athersys

United States Founded: 1995 • Age: 31 yrs
Stem Cell Therapy for the treatment of cardiovascular disease areas

About Athersys

Athersys is a company based in United States founded in 1995.. Athersys has raised $74.43 million across 16 funding rounds from investors including HHS, Invesco Mutual Fund and Helios. Athersys operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.

  • Headquarter United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Athersys, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $5.33 M
    -3.43
    as on Dec 31, 2022
  • Net Profit
    $-72.53 M
    16.58
    as on Dec 31, 2022
  • EBITDA
    $-75.59 M
    11.48
    as on Dec 31, 2022
  • Total Equity Funding
    $74.43 M (USD)

    in 16 rounds

  • Latest Funding Round
    $7.04 M (USD), Post-IPO

    Mar 30, 2020

  • Investors
    HHS

    & 11 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Athersys

Athersys is a publicly listed company on the OTC with ticker symbol ATHXQ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: OTC · Ticker: ATHXQ . Sector: Health technology · USA
People of Athersys
Headcount 50-200
Employee Profiles 3
Board Members and Advisors 3
Employee Profiles
People
Robert Mays
EVP & Head, Regenerative Medicine & Neuroscience Programs
People
Brooke Dapolito, MBA
Director, Regulatory Project Management

Unlock access to complete

Funding Insights of Athersys

Athersys has successfully raised a total of $74.43M across 16 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.04 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 16
  • Last Round Post-IPO — $7.0M
  • First Round

    (08 May 2000)

  • Investors Count 12
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2020 Amount Post-IPO - Athersys Valuation

investors

Nov, 2019 Amount Post-IPO - Athersys Valuation

investors

Aug, 2017 Amount Grant - Athersys Valuation

investors

HHS
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Athersys

Athersys has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Invesco Mutual Fund and Helios. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Greenleaf Capital Partners is engaged in investment and business consulting.
Founded Year Domain Location
Government-backed investments are directed toward healthcare, fintech, and various sectors.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Athersys

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Athersys

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Athersys Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Athersys

Athersys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical products are manufactured and marketed worldwide.
domain founded_year HQ Location
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
domain founded_year HQ Location
Biopharmaceutical research and drug development are conducted globally by AbbVie.
domain founded_year HQ Location
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
domain founded_year HQ Location
Traditional pharmaceutical medicines are developed for multiple health fields.
domain founded_year HQ Location
Developer of drugs for the treatment of multiple disorders
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Athersys

Frequently Asked Questions about Athersys

When was Athersys founded?

Athersys was founded in 1995 and raised its 1st funding round 5 years after it was founded.

Where is Athersys located?

Athersys is headquartered in United States.

Is Athersys a funded company?

Athersys is a funded company, having raised a total of $74.43M across 16 funding rounds to date. The company's 1st funding round was a Grant of $83.41K, raised on May 08, 2000.

What is the annual revenue of Athersys?

Annual revenue of Athersys is $5.33M as on Dec 31, 2022.

What does Athersys do?

Athersys engaged in the discovery and development of therapeutic product candidates to treat different cardiovascular, neurological, inflammatory diseases. Its product portfolio includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications such as Ischemic stroke, Acute myocardial infarction, Inflammatory bowel disease. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.

Who are the top competitors of Athersys?

Athersys's top competitors include Merck, Roivant Sciences and AbbVie.

Is Athersys publicly traded?

Yes, Athersys is publicly traded on OTC under the ticker symbol ATHXQ.

Who are Athersys's investors?

Athersys has 12 investors. Key investors include HHS, Invesco Mutual Fund, Helios, Aspire Capital, and Greenleaf Capital Partners.

What is Athersys's ticker symbol?

The ticker symbol of Athersys is ATHXQ on OTC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available